Trials / Completed
CompletedNCT00556179
Lactoserum (Dermacyd Femina®) and Prevention of Recurrence of Bacterial Vaginosis
Local, National (Brazil), Multicentric, Open, Non-Controlled, Phase IV, Study of Lactoserum (Dermacyd Femina®), in Women at Reproductive Age, to Prevent Recurrence of Bacterial Vaginosis, During Three Months, After Standard Treatment With Metronidazole.
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 122 (actual)
- Sponsor
- Sanofi · Industry
- Sex
- Female
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to demonstrate if the use of Dermacyd can avoid the recurrence of bacterial vaginosis after three months of the standard treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lactoserum (Dermacyd Femina®) | Once a day during three months |
Timeline
- Start date
- 2007-09-01
- Primary completion
- 2008-12-01
- First posted
- 2007-11-09
- Last updated
- 2009-01-22
Locations
1 site across 1 country: Brazil
Source: ClinicalTrials.gov record NCT00556179. Inclusion in this directory is not an endorsement.